Dr. Reddys Laboratories is currently trading at Rs. 3085.25, up by 38.90 points or 1.28% from its previous closing of Rs. 3046.35 on the BSE.
The scrip opened at Rs. 3066.25 and has touched a high and low of Rs. 3115.00 and Rs. 3066.25 respectively. So far 10485 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3353.85 on 25-Sep-2014 and a 52 week low of Rs. 2250.00 on 19-May-2014.
Last one week high and low of the scrip stood at Rs. 3185.00 and Rs. 2995.05 respectively. The current market cap of the company is Rs. 52475.23 crore.
The promoters holding in the company stood at 25.49% while Institutions and Non-Institutions held 43.79% and 13.69% respectively.
Dr. Reddy’s Laboratories has launched Sirolimus Tablets 1 mg and 2 mg, a therapeutic equivalent generic version of RAPAMUNE (Sirolimus) tablets in the US market on October 27, 2014, following the approval by the United States Food & Drug Administration (USFDA). The company’s Sirolimus tablets in 1 mg and 2 mg are available in bottle counts of 100.
According to IMS Health, the RAPAMUNE tablets brand had US sales of approximately $206 million MAT for the most recent twelve months ending in August 2014.
Dr. Reddys is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
No comments:
Post a Comment